`
`
`
`Plaintiffs,
`
`
`
`v.
`
`
`
`
`
`
`C.A. No. 16-1221 (LPS)
`CONSOLIDATED
`
`BAYER HEALTHCARE LLC and
`BAYER HEALTHCARE
`PHARMACEUTICALS INC.,
`
`
`
`
`
`TEVA PHARMACEUTICALS USA, INC.,
`et al.,
`
`
`
`
`
`
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`NOTICE OF DEPOSITION
`PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 30(b)(6)
`
`PLEASE TAKE NOTICE that commencing on July 30, 2018, at the law office of
`
`
`
`Defendants.
`
`Williams & Connolly LLP, 725 Twelfth Street, NW, Washington, DC 20005, or at such time and
`
`place that is agreed upon by the parties, Plaintiffs Bayer HealthCare LLC and Bayer HealthCare
`
`Pharmaceuticals Inc. (collectively, “Bayer”), through their attorneys, will take the deposition of
`
`Apotex Corp. and Apotex Inc. (collectively, “Apotex”) pursuant to Rule 30(b)(6) of the Federal
`
`Rules of Civil Procedure.
`
`At the time of the deposition, Apotex shall designate one or more of its directors, officers,
`
`managing agents, or other persons who will testify on behalf of Apotex as to all information
`
`known or reasonably available to Apotex regarding the subject matters set forth in
`
`Attachment A.
`
`The deposition will take place upon oral examination before a notary public or other
`
`person authorized to administer oaths, will be recorded by stenographic and/or sound-and-video
`
`means, and will continue from day to day until completed. You are invited to attend and
`
`participate.
`
`
`
`
`
`Case 1:16-cv-01221-LPS Document 65 Filed 07/12/18 Page 2 of 8 PageID #: 611
`
`
`
`
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`/s/ Anthony D. Raucci
`
`
`
`
`Jack B. Blumenfeld (#1014)
`Derek J. Fahnestock (#4705)
`Anthony D. Raucci (#5948)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@mnat.com
`dfahnestock@mnat.com
`araucci@mnat.com
`
`Attorneys for Plaintiffs Bayer HealthCare LLC
`and Bayer HealthCare Pharmaceuticals Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`OF COUNSEL:
`
`Bruce R. Genderson
`Adam L. Perlman
`Dov P. Grossman
`Jessica B. Rydstrom
`Seth R. Bowers
`Ben Picozzi
`WILLIAMS & CONNOLLY LLP
`725 Twelfth St. NW
`Washington, DC 20005
`(202) 434-5000
`
`July 12, 2018
`
`
`2
`
`
`
`Case 1:16-cv-01221-LPS Document 65 Filed 07/12/18 Page 3 of 8 PageID #: 612
`
`
`
`ATTACHMENT A
`
`INSTRUCTIONS AND DEFINITIONS
`
`As used herein, the terms “you,” “your,” “yours,” and “Apotex” mean jointly and
`
`1.
`
`severally defendants Apotex Corp., Apotex Inc., their officers, directors, employees, divisions,
`
`parent companies, subsidiaries, affiliates, and predecessors or successors-in-interest, any joint
`
`venture to which they may be a party, consultants, agents, and accountants, including any person
`
`who served in any such capacity at any time.
`
`2.
`
`As used herein, “Teva” means
`
`jointly and severally defendant Teva
`
`Pharmaceuticals USA, Inc., its officers, directors, employees, divisions, parent companies,
`
`subsidiaries, affiliates, and predecessors or successors-in-interest, any joint venture to which it
`
`may be a party, consultants, agents, and accountants, including any person who served in any
`
`such capacity at any time.
`
`3.
`
`As used herein, the term “including” means “including but not limited to” or
`
`“including without limitation.”
`
`4.
`
`As used herein, the terms “and” as well as “or” shall be construed either
`
`disjunctively or conjunctively, and references shall be construed either as singular or plural, as
`
`necessary to bring within the scope of these topics any information that might otherwise be
`
`construed to be outside their scope.
`
`5.
`
`As used herein, the term “all” shall be construed to mean all or any, and the term
`
`“any” shall be construed to mean all or any.
`
`6.
`
`As used herein, the term “communication” means any transmission of any
`
`information from one person to another, including, without limitation, by personal meeting,
`
`telephone, facsimile, electronic transmission, including electronic mail, and teleconference.
`
`
`
`
`
`Case 1:16-cv-01221-LPS Document 65 Filed 07/12/18 Page 4 of 8 PageID #: 613
`
`
`
`7.
`
`As used herein, “Apotex’s ANDA Product” shall be construed to include any
`
`product that is the subject of Abbreviated New Drug Application (“ANDA”) No. 203085, as well
`
`as the active pharmaceutical ingredient drug substance(s) identified therein, including but not
`
`limited to any generic equivalent of Stivarga®.
`
`8.
`
`As used herein, “regorafenib” shall mean the compound of the formula:
`
`
`
`(also known as, inter alia, 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-
`
`pyridine-2-carboxylic acid methylamide), or any salt form (including, but not limited to a
`
`hydrochloride salt) of the compound, or any solvate (including, but not limited to, any hydrate)
`
`of any of the aforementioned, or any polymorph of the aforementioned, or any other form of any
`
`of the aforementioned, or any mixture of two or more of the aforementioned, and includes but is
`
`not limited to the active pharmaceutical ingredient (“API”) in Stivarga®.
`
`9.
`
`As used herein, the term “FDA” means the United States Food and Drug
`
`Administration, including without limitation its employees, scientists, technicians, agents,
`
`examiners, and laboratories.
`
`10.
`
`As used herein, the terms “person” and “entity” mean any natural person and any
`
`other cognizable entity, including, without limitation, corporations, proprietorships, partnerships,
`
`joint ventures, businesses, consortiums, clubs, associations, foundations, governmental agencies
`
`or instrumentalities, societies, and orders.
`
`11.
`
`As used herein, “Apotex’s Notice Letters” means the Notice Letters sent from
`
`Apotex to Bayer on or about November 8, 2016 and March 17, 2017.
`
`2
`
`
`
`Case 1:16-cv-01221-LPS Document 65 Filed 07/12/18 Page 5 of 8 PageID #: 614
`
`
`
`12.
`
`13.
`
`14.
`
`15.
`
`As used herein, the term “’553 patent” means United States Patent No. 8,637,553.
`
`As used herein, the term “’107 patent” means United States Patent No. 9,458,107.
`
`As used herein, the term “Patents-in-Suit” means the’553 and ’107 patents.
`
`The use of the singular form of any word includes the plural and vice versa, as
`
`necessary to bring within the scope of these topics any information or documents and things that
`
`might otherwise be construed to be outside their scope.
`
`
`
`1.
`
`The process by which Apotex identified regorafenib as a candidate for a potential
`
`TOPICS
`
`Abbreviated New Drug Application and which individuals and entities were involved in that
`
`process.
`
`2.
`
`The decision to file ANDA No. 203085, the information considered in reaching
`
`that decision, and the individuals and entities involved in that decision.
`
`3.
`
`All patent certifications in connection with ANDA No. 203085, any amendments
`
`or supplements thereto, which individuals were involved in the patent certifications, and what
`
`information was considered.
`
`4.
`
`The contents of the proposed labeling for Apotex’s ANDA Product, the decision-
`
`making as to the contents of the proposed label for Apotex’s ANDA Product, which individuals
`
`and entities were involved in the decision-making, and the contents of any discussions related in
`
`any way to the decision-making.
`
`5.
`
`6.
`
`7.
`
`8.
`
`The projected sales and market share of Apotex’s ANDA Product.
`
`The indications for Apotex’s ANDA Product.
`
`Apotex’s pricing practices as they pertain to Apotex’s ANDA Product.
`
`Apotex’s anticipated profits and/or losses from sale of Apotex’s ANDA Product.
`
`3
`
`
`
`Case 1:16-cv-01221-LPS Document 65 Filed 07/12/18 Page 6 of 8 PageID #: 615
`
`
`
`9.
`
`10.
`
`Product.
`
`11.
`
`12.
`
`Apotex’s marketing or planned marketing of Apotex’s ANDA Product.
`
`Any actual, potential, or anticipated commercial launch of Apotex’s ANDA
`
`The preparation and contents of Apotex’s Notice Letters.
`
`All manufactured batches of Apotex’s ANDA Product, including the batch size,
`
`batch number, or other identifying notation, and dates of manufacture and delivery.
`
`13.
`
`Any novelty, patentability, validity, due diligence, or freedom-to-operate search,
`
`evaluation, or investigation conducted by or on behalf of Apotex relating to the subject matter of
`
`any of the Patents-in-Suit.
`
`14.
`
`The polymorphic form of regorafenib in Apotex’s ANDA Product and any
`
`analyses of the polymorphic form of regorafenib in Apotex’s ANDA Product.
`
`15.
`
`Any metabolites generated by the use of Apotex’s ANDA Product in accordance
`
`with
`
`its
`
`labeling,
`
`including
`
`the
`
`identification
`
`thereof and
`
`their contribution
`
`to
`
`the
`
`pharmacological properties of Apotex’s ANDA Product.
`
`16.
`
`Any anilinic impurities contained in Apotex’s ANDA Product, including the
`
`identification thereof and any analyses to determine the quantity of anilinic impurities in
`
`Apotex’s ANDA Product.
`
`17.
`
`Any anilinic impurities contained in the regorafenib used to make Apotex’s
`
`ANDA Product, including the identification thereof and any analyses to determine the quantity
`
`of anilinic impurities in said regorafenib.
`
`18.
`
`The impurity specifications/limits (including for any anilinic impurity) for
`
`Apotex’s ANDA Product, including what they are, how they were determined, and who was
`
`involved in determining those specifications/limits.
`
`4
`
`
`
`Case 1:16-cv-01221-LPS Document 65 Filed 07/12/18 Page 7 of 8 PageID #: 616
`
`
`
`19.
`
`The impurity specifications/limits (including for any anilinic impurity) for the
`
`regorafenib used to make Apotex’s ANDA Product, including what they are, how they were
`
`determined, and who was involved in determining those specifications/limits.
`
`20.
`
`The process for synthesizing the regorafenib used to make Apotex’s ANDA
`
`Product, including identity of the starting materials, reagents, intermediates, and side products.
`
`21.
`
`The assays used to measure any anilinic impurities in Apotex’s ANDA Product
`
`and the development thereof.
`
`22.
`
`The assays used to measure any anilinic impurities in regorafenib used for
`
`Apotex’s ANDA Product and the development thereof.
`
`23.
`
`Any agreements between Apotex and Teva related to regorafenib, Stivarga®, a
`
`generic version of Stivarga®, Apotex’s ANDA Product, or this litigation.
`
`24.
`
`All communications between Teva and Apotex relating to regorafenib, Stivarga®,
`
`a generic version of Stivarga®, Apotex’s ANDA Product, or this litigation.
`
`5
`
`
`
`Case 1:16-cv-01221-LPS Document 65 Filed 07/12/18 Page 8 of 8 PageID #: 617
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on July 12, 2018, I caused the foregoing to be electronically filed
`
`with the Clerk of the Court using CM/ECF, which will send notification of such filing to all
`
`registered participants.
`
`
`
`I further certify that I caused copies of the foregoing document to be served on
`
`July 12, 2018, upon the following in the manner indicated:
`
`VIA ELECTRONIC MAIL
`
`VIA ELECTRONIC MAIL
`
`/s/ Anthony D. Raucci
`_____________________________________
`Anthony D. Raucci (#5948)
`
`Kenneth L. Dorsney, Esquire
`Morris James LLP
`500 Delaware Avenue, Suite 1500
`Wilmington, DE 19801-1494
`Attorneys for Defendants Apotex Inc.
`and Apotex Corp.
`
`Stephen R. Auten, Esquire
`Richard T. Ruzich, Esquire
`Phillip Y. Kouyoumdjian, Esquire
`Ian Scott, Esquire
`Taft Stettinius & Hollister LLP
`111 East Wacker Drive, Suite 2800
`Chicago, IL 60601
`Attorneys for Defendants Apotex Inc.
`and Apotex Corp.
`
`
`
`
`
`
`
`